J.A.R. Laboratories' LidoPatch as effective as Rx lidocaine in clinical trials
CHICAGO — J.A.R. Laboratories on Tuesday announced the results of a trial comparing its OTC LidoPatch (lidocaine 3.6%, menthol 1.25%), prescription (Rx) (lidocaine 5%) and placebo in patients who suffer from arthritis and back pain.
The OTC patch was proven as effective as Rx lidocaine patches by significantly improving patients' pain, mood and ability to perform normal activities when compared to placebo.
Switching to OTCs from Rx's can provide benefits to patients and payers alike, J.A.R Laboratories noted. There is the potential for less cost to the patient and could reduce the number of visits to their doctor. Payers gain an advantage by switching to a lower cost product and less resource utilization by its members.
Back pain is the second most common reason for a physician's visit in the USA and the second most common reason to miss work.